Neil Kumar sold $5.7M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 80,000 shares at an average of $71.86, traded Feb 10, 2026, filed Feb 12, 2026.
Score components
- +25RoleCEO
- +25Trade size$5.7M at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000118, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -14,201 | $71.80 | $1.0M | 701,485 | Feb 12, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,799 | $72.28 | $419k | 695,686 | Feb 12, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -14,040 | $71.80 | $1.0M | 4,504,407 | Feb 12, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,960 | $72.27 | $431k | 4,498,447 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,806 | $70.69 | $552k | 687,880 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -3,716 | $71.44 | $265k | 684,164 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -4,484 | $72.64 | $326k | 679,680 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -3,994 | $73.25 | $293k | 675,686 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,860 | $70.70 | $556k | 4,490,587 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -3,775 | $71.46 | $270k | 4,486,812 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -4,404 | $72.65 | $320k | 4,482,408 | Feb 12, 2026 |
| Feb 11, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -3,961 | $73.25 | $290k | 4,478,447 | Feb 12, 2026 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.5M 80,000 shares | -12% | |
| 35Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $624k 8,671 shares | -54% | |
| 40Moderate | BridgeBio Pharma, Inc. | Andrea Ellis director | $4.2M 64,921 shares | -78% | |
| 40Moderate | BridgeBio Pharma, Inc. | Hannah Valantine director | $1.7M 25,484 shares | -77% | |
| 21Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $132k 2,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $2.0M 28,053 shares | -11% | |
| 16Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $38k 510 shares | -0% | |
| 27Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $755k 10,000 shares | -46% | |
| 42Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $1.0M 13,600 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.